Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVC-COV1901 in adolescents
NCT04951388Phase 2Completed
- Sponsor
- Medigen Biotechnology
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing MVC-COV1901 with Placebo (2 arms). Primary endpoints: Incidence of Adverse Events and Immunogenicity of MVC-COV1901. Started Jul 2021; status: completed.
02
Drugs
MVC-COV1901
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04951388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04951388.